Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Colorectal cancer is the 3rd most common cancer in France and the 2nd cause of death from cancer. Between 30 to 60% of patients develop limited or predominant liver metastases. Surgical resection of these metastases, only curative treatment is not immediately possible in 10-15% of cases. In unresectable patients, current palliative treatments are based on systemic chemotherapy associated or not with the targeted therapies (anti-EGFR (panitumumab), anti-VEGF (bevacizumab)). In this patient population, special attention was paid to intensified treatment regimens in order to improve their efficie

Trial Details

NCT ID
NCT02885753
Phase
PHASE3
Sponsor
Federation Francophone de Cancerologie Digestive
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Oxaliplatin intravenous
  • 5 FU bolus
  • Folinic acid
  • Oxaliplatin intra-arteriel
  • Panitumumab
  • Bevacizumab
Locations (sample)
  • Brussels, Belgium|50.85045,4.34878
  • Angers, France|47.47156,-0.55202
  • Angers, France|47.47156,-0.55202
  • Antony, France|48.75329,2.29668
  • Avignon, France|43.94834,4.80892

Key Eligibility Criteria

  • Histologically proven colorectal adenocarcinoma with hepatic metastasis(es)
  • At least one measurable hepatic metastasis according to the criteria RECIST v1.1
  • No other metastatic sites except lung nodules if number ≤ 3 and \< 10 mm
  • RAS mutation status known (determination of KRAS mutation (exons 2,3 and 4) and determination of the NRAS mutation (exons 2,3 and 4))

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →